



Firstar Plaza
P.O. Box 2113
Madison, Wisconsin 53701-2113
608/251-5000
FAX 608/251-9166
<http://www.quarles.com>

Attorneys at Law in
Milwaukee and Madison, Wisconsin
West Palm Beach and Naples, Florida
Phoenix, Arizona

July 14, 1998

Assistant Commissioner of Patents
Box Patent Application
Washington DC 20231

Re: Filing New Patent Application

Dear Sir:

Enclosed for filing please find a new patent application
entitled: METHOD FOR IDENTIFYING MUTANTS AND MOLECULES

by William F. Dove
Alexandra Shedlovsky

The undersigned hereby certifies that this document is being deposited with the United States Postal Service today, July 14, 1998, by the "Express Mail" service, utilizing Express Mail label number EE450090526US, addressed to: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Please indicate receipt of this application by returning the attached postcard with the official Patent and Trademark Office receipt and serial number stamped thereon.

Respectfully submitted,



QBMAD\165635
Enclosures

FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1.
These are the fees effective October 1, 1997.
Small Entity payments must be supported by a small entity statement
otherwise large entity fees must be paid. See Forms PTO/SB/09-12

TOTAL AMOUNT OF PAYMENT \$ 655.00

Complete if Known	
Application Number	
Filing Date	
First Named Inventor	William F. Dove
Group Art Unit	
Examiner Name	
Attorney Docket Number	960296. 95491

METHOD OF PAYMENT (check one)

1. The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 17-0055

Deposit Account Name Quarles & Brady

Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 Charge the Issue Fee Set in 37 CFR 1.18 at the Mailing of the Notice of Allowance, 37 CFR 1.311(b)

Payment Enclosed: Check Money Order Other

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee
105	130	205
127	50	227
139	130	139
147	2,520	147
112	920	112
113	1,840	113
115	110	215
116	400	216
117	950	217
118	1,510	218
128	2,060	228
119	310	219
120	310	220
121	270	221
138	1,510	138
140	110	240
141	1,320	241
142	1,320	242
143	450	243
144	670	244
122	130	122
123	50	123
126	240	126
581	40	581
146	790	246
149	790	249

Surcharge - late filing fee or oath
Surcharge - late provisional filing fee or cover sheet
Non-English specification
For filing a request for reexamination
Requesting publication of SIR prior to Examiner action
Requesting publication of SIR after Examiner action
Extension for reply within first month
Extension for reply within second month
Extension for reply within third month
Extension for reply within fourth month
Extension for reply within fifth month
Notice of Appeal
Filing a brief in support of an appeal
Request for oral hearing
Petition to institute a public use proceeding
Petition to revive unavoidably abandoned application
Petition to revive unintentionally abandoned application
Utility issue fee (or reissue)
Design issue fee
Plant issue fee
Petitions to the Commissioner
Petitions related to provisional applications
Submission of Information Disclosure Stmt
Recording each patent assignment per property (times number of properties)
Filing a submission after final rejection (37 CFR 1.129(a))
For each additional invention to be examined (37 CFR 1.129(b))

FEE CALCULATION (fees effective 10/01/97)

1. FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
101	790	201	395 Utility filing fee
106	330	206	165 Design filing fee
107	540	207	270 Plant filing fee
108	790	208	395 Reissue filing fee
114	150	214	75 Provisional filing fee

SUBTOTAL (1) (\$395.00)

2. CLAIMS

Total Claims	Extra	Fee from below	Fee Paid
25	-20**=	5 X 11 =	55.00
8	-3**=	5 X 41 =	205.00

Multiple Dependent Claims

** or number previously paid, if greater. For reissues see below	
Large Entity Fee Code (\$)	Small Entity Fee Code (\$)
103	22
102	82
104	270
109	80
110	22

Fee Description	
Claims in excess of 20	
Independent claims in excess of 3	
Multiple dependent claim	
**Reissue independent claims over original patent	
**Reissue claims in excess of 20 and over original patent	


SUBTOTAL (2) (\$260.00)

Other fee (specify) _____
Other fee (specify) _____

SUBTOTAL (3) (\$)

Reduced by Basic Filing Fee Paid

SUBMITTED BY

Typed or Printed Name	Complete if applicable
Bennett J. Berson	Reg. Number 37,094
	Date July 14, 1998
QBMAD165639	Deposit Account User ID

METHOD FOR IDENTIFYING MUTANTS AND MOLECULES

5

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of application serial number 08/751,292 filed November 18, 1996, incorporated herein in its entirety by reference.

10

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not applicable.

BACKGROUND OF THE INVENTION

15 Worldwide efforts to determine the genomic DNA sequences of humans and other animals are ongoing. Such efforts typically focus on obtaining sequence information from cDNAs in libraries created from RNAs of various tissues. Thus, collections of "expressed sequence tags" (ESTs) include portions of coding regions from most human genes.

20 Although ESTs provide useful structural information, they offer little insight into the functional relationship among genes. The functional relationship is of particular importance to determining the set of genes involved in a biological process and, subsequently, to developing pharmaceutical agents that affect one or more of the components of the biological process. See, e.g., Friedrich, G. A., "Moving Beyond the Genome Projects: Does the Future of Genomics-Based Drug Discovery Lie With the Mouse?," Nature Biotechnology 14:1234-1237 (1996).

25 Friedrich argues in favor of using model systems that mirror human physiology in determining which genes may be involved in a biological process, and suggests that the mouse is an excellent model organism for human biology in that it shares with humans most salient aspects of mammalian physiology. The genomes of mice and humans are approximately the same in size, organization, and structure. Friedrich

30

35

proposes that the mouse can be developed as an effective tool for drug development. Friedrich puts forth a "radical" suggestion that there is no logical barrier hindering large-scale phenotypic screens using mice.

5 Friedrich proposes using an insertional mutagen in embryonic stem cells to generate random mutations in the mouse genome, then screening for a variety of pre-determined phenotypes and cloning affected genes.

10 In particular, the physiology of, and treatments for, colon cancer are of particular biomedical interest. Colon cancer is one of the most prevalent malignancies in the Western world, with an estimated 145,000 new cases and 60,000 deaths each year in the United States alone. Genetic factors play a key role in this disease. Mutations in the human adenomatous polyposis coli (*APC*) gene cause a set of familial colon cancer syndromes. Mice carrying a mutation in a corresponding gene (*Apc*) also develop many intestinal adenomas. Heterozygotes for the *Min* (Multiple Intestinal Neoplasia) allele of the mouse *Apc* gene develop numerous intestinal and colonic adenomas [on average 29 Å 10, on a C57BL/6J (or equivalent derivative) background] that are similar in morphology to the adenomas seen in human inherited colonic polyposis syndromes such as familial adenomatous polyposis and Gardner's syndrome. *Min/Min* homozygotes die in utero. The *Min* mutation maps to mouse chromosome 18. The sequence of the *Apc* gene is known and published. *Min* mice carry a nonsense mutation in exon 15 of the mouse *Apc* gene (a mutation of the sort typically seen in human colon cancer kindreds). Mice carrying *Min* thus provide a model system for studying human familial adenomatous polyposis.

15 30 A locus (*Mom-1*) that strongly modifies the tumor number in heterozygous *Min/+* mice was mapped to distal chromosome 4. Dietrich, W.F., et al., "Genetic Identification of *Mom-1*, a major modifier locus affecting *Min*-induced intestinal neoplasia in the mouse," *Cell*, 75:631-639 (1993). *Mom-1* lies in a region of synteny conservation with human chromosome 1p35-36, a region of frequent somatic loss of heterozygosity in a variety of human tumors, including colon tumors. *Mom-1* is only one of an

unknown number of loci that modify the expression of an inherited cancer syndrome, and it does not explain all of the genetic variation in tumor number in intraspecific backcrosses.

What is lacking is a systematic method for pinpointing 5 genetic loci involved in modifying known phenotypes, by enhancing or suppressing. In the particular case of colon cancer in humans and animals, it would be desirable to locate the sequences in the genome (and the molecules encoded by those sequences) that are involved in the appearance of intestinal 10 adenomas. The lack of such a systematic method has limited understanding of oncogenesis and, as such, has precluded development of pharmaceuticals that modify the oncogenic process. A systematic method should include not only non-essential loci, for which numerous mutant alleles can be 15 found among homozygous inbred mouse strains, but also essential loci, for which mutant alleles in heterozygous form may influence the phenotype. Mutations that inactivate an essential gene will normally be lethal when homozygous, and so will not be found among inbred mouse strains.

20 BRIEF SUMMARY OF THE INVENTION

The present invention permits detection of a genetic locus or loci that can modify a chosen known phenotype conferred by a chosen dominant allele. The method includes a mutagenic 25 process that facilitates identifying and isolating the genetic sequences that encode the molecules that can modify the chosen phenotype, as well as the phenotype-modifying molecules themselves.

The method can be practiced using inbred strains of non- 30 human animals, which are preferably mammals, and more preferably rodents. Inbred strains of mice, rats and rabbits are available. In the present method, mice are the non-human mammalian animals of choice, because of the synteny between humans and mice and because the genetics and breeding of mice are highly developed. Further, the mouse can exhibit disease 35 phenotypes that are very similar to those of humans, as in the exemplified embodiment. The murine genetic sequences and the

molecules obtained in the method are used to secure corresponding sequences and molecules from humans. The human sequences and molecules are then employed in known methods to develop pharmaceutical agents.

5 The basic breeding method includes the following steps. Each of a set of mice of a founder inbred mouse strain is mutagenized and then bred to the same inbred strain to produce an inbred holding generation ("Generation 1" or "Gen1"). The animals of the Gen1 founder mouse strain carry random point 10 mutations relative to wild-type mice of that strain. Gen1 mice are outcrossed with a mouse of an index inbred mouse strain to obtain Gen1F₁ progeny. The index inbred mouse strain carries a dominant allele at a locus known to confer a chosen phenotype. The chosen phenotype is designated the "index phenotype." The 15 index phenotype, which focuses the screening method on the phenotype of interest, is characterized in an index strain and provides a reference phenotype against which possible mutants can be compared. The dominant index allele can include any condition that brings a biological process into a range in which it responds to heterozygous enhancer or suppressor 20 mutations of the sort identified in the present invention. The condition can be a cognizable genetic condition or might even be a non-genetic environmental condition. At least some of the Gen1 F₁ progeny carry both the dominant allele and at least one random mutation that may modify the index phenotype conferred by the dominant allele. A founder animal is judged to be of interest if a subset of its Gen1F₁ progeny are extensively 25 modified for the index phenotype.

When a founder mouse has at least one Gen1F₁ offspring 30 that displays a modified phenotype relative to control animals, the founder (Gen1) animal is crossed to an unmutagenized mouse of the founder strain to produce second generation (Gen2) offspring. Those offspring are again outcrossed to the index strain to obtain Gen2F₁ progeny. The presence of a phenotype-modifying mutation is then verified if a subset of the Gen2F₁ 35 progeny are also modified for the index phenotype. Again, a cluster of animals with modified index phenotypes gives

increasing confidence that the Gen1 founder carries a mutation of interest.

Genetic material that comprises the phenotype-modifying mutation can then be obtained using methods known to the art. Molecules encoded by the genetic material may also be obtained. The obtained genetic materials and molecules (or corresponding human equivalents) are used in methods known to the art to produce pharmaceutical agents that can ameliorate phenotypes noted in human or non-human patients affected in the biological process of interest.

It is an object of the present invention to provide a rapid, focused approach to obtaining genes in a model mammalian organism that can affect a biomedically-relevant phenotype.

It is an advantage of the present invention that the method can simultaneously identify an ensemble of several genes that can modify the index phenotype.

It is another advantage of the present invention that the method can uncover genes having no other known phenotype.

The present invention offers advantages over existing methods of obtaining genes, such as analysis of ESTs, in that genes secured in the present method are necessarily relevant to a biological phenotype. In contrast, genome-sequencing methods can provide voluminous sequence information for many genes, but offer little or no guidance as to the functional relationship among sequenced genes.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

Fig. 1 depicts the probability of survival of Gen1F₁ mice bred in accordance with the method of the present invention.

Fig. 1 also depicts the survival times of individuals of four kindreds that exhibited progeny with longer or shorter survival times relative to the average survival time of Gen1F₁ mice carrying the index *Min* allele. Longer-surviving suppressor (Su) candidate kindreds 248 and 258 are shown as squares.

Shorter-surviving enhancer (En) candidate kindreds 333 and 425 are shown as circles.

DETAILED DESCRIPTION OF THE INVENTION

A goal of the present invention is to identify genetic loci and genetic sequences that can modify a known phenotype. Although such analysis employing mutagenesis cannot be performed in humans for ethical reasons, the synteny and sequence conservation between human and mouse genomes provides a facile bridge to identify such loci and sequences in the human. It is likely that such sequences will correlate with existing human genetic sequence information. Thus, equivalent loci and genetic sequences can be sought in the human genome using conventional, available hybridization and PCR techniques.

5 The method is an Index-directed, Cluster-enhanced, Modifier locus and Molecule identification method that can be referred to as an "ICMM method."

10 The availability of inbred mice having a well defined genetic composition and well-studied phenotypes that model human syndromes, diseases, and other conditions, makes the mouse the preferred mammalian species in which to practice the present method. A preferred mouse species is *Mus musculus*.

15 The breeding system described herein is premised upon the existence of a phenotype that is evident in mice heterozygous for the allele that confers the chosen index phenotype. It is always preferable to employ an index strain that carries an allele that gives the index phenotype in the heterozygous state. The index phenotype can be made "evident" by visual, biochemical, or other detection means. The phenotype-controlling allele can be lethal when present in the homozygous state. For cancer, the phenotype can relate either to effects that follow from the presence of an activated 20 cancer-inducing allele or else from inactivation of a tumor suppressor gene that causes tumor formation in the absence of one normal copy of the gene. The phenotype can be governed by an allele on a sex chromosome or on an autosome. If the allele is on a sex chromosome, the breedings described herein are 25 modified in a manner known to the art to ensure that the allele is maintained in the breeding pool.

30 The index phenotype is preferably conferred by a single

dominant allele, although by taking care to produce suitable founder animals, phenotypes under the control of more than one locus can be studied in the method. It is not necessary that the phenotype-conferring allele is a defined genetic sequence, but rather the allele can be defined by classical genetic methods. It is advantageous that the allele is tightly linked to a genetic marker for genotype analysis, as is described elsewhere herein. With the dense microsatellite map of the mouse genome currently available, this condition is always met.

10 Phenotype-modifying loci are obtained in the present invention. A "modification" is any demonstrable change in an index phenotype relative to control animals lacking the phenotype-modifying allele, including, without limitation, enhancing or suppressing a phenotype, such as prolonging or shortening an animal's life span or circadian behavior. It is not necessary that the whole animal be affected by the

15 modification. For example, a modified phenotype may be a change in a particular behavior or a change in the level of a particular biomolecule, such as a blood protein, after introducing a phenotype-modifying mutant allele in the method of the present invention. The assay for modified outliers in the first stage of the screen, Gen1F₁, will usually be relatively crude. One must judge whether an outlier is in the first or last 10 percentile range of the phenotypic distribution. For example, in a strain of mice having a well-defined running activity governed by a single dominant mutation (*Clock*), the method described herein can be used to obtain animals having modified timing of that running activity. The genetic material (and protein molecules) responsible for that modification can be obtained by mapping and positionally cloning the modifying mutation.

20 The system is particularly amenable to study of genetic interactions in cancers known to have a genetic component. In particular, humans that carry an aberrant *APC* gene are predisposed to develop numerous tumors in the intestinal tract. Mice heterozygous for the *Min* allele of *Apc*, the murine homolog 25 of human *APC*, also develop numerous tumors in the intestinal

tract, similar to human inherited colonic polyposis syndromes. It is demonstrated herein that mutations induced in the genome elsewhere than at the *Apc* locus can modify the survival rate and intestinal tumor load of mice carrying the *Min* allele at that locus.

Several important breeding considerations direct the selection of inbred mouse strains for use in the method. It is understood that those skilled in the art of mouse breeding are familiar with the breeding requirements of available mouse strains and such requirements need not be restated here.

The strain into which random mutations are introduced must be an inbred strain so that all modifications are the result of induced mutagenesis rather than genomic divergence. The strain should be susceptible to efficient germline mutagenesis. By

"susceptible" the applicants intend that the strain have characteristic forward mutation rates of at least 1/500 per gamete per locus. In addition, the strain should have a long breeding span of at least one year. Also, it is preferred that the strain yield large litters, on average 8 or more pups per litter. A strain meeting these requirements is the inbred strain BTBR, which is available from the Jackson Laboratory, Bar Harbor, Maine.

It is important that the inbred strain in which mutations are induced can be distinguished from the strain that contains the phenotype-conferring allele, e.g., by restriction fragment length polymorphisms (RFLP) or by simple sequence length polymorphisms (SSLP). A high incidence of informative differences in standard genetic markers between the two strains is important for mapping and cloning any mutation of interest.

In one embodiment of the invention, the index phenotype (*Min*) was provided on a background of C57BL/6J (or equivalent derivative) (hereinafter, "B6-*Min*"). An "equivalent derivative" has an index phenotype comparable to that of B6-*Min* on a genuine C57BL/6J background. The BTBR strain used for mutagenesis in this embodiment is polymorphic at approximately half of the SSLP marker loci, relative to the B6 inbred strain. In heterozygous form, BTBR has no strong effect on the *Min*

phenotype.

It is also important that the two strains used in the method be relatively free of polymorphic dominant modifiers of the chosen index phenotype. By "relatively free" the applicants intend that differences in the index phenotype between Gen1F₁ animals and the index strain be sufficiently minor so as not to mask the effects of newly induced mutations. One skilled in the art will be able to determine the permissible variation for any given index phenotype. For example, in the case of the *Min* index phenotype, Gen1F₁ animals should show no more than about a 1.5-fold change in tumor multiplicity compared to B6-*Min*. In the *Clock* case, there should be no more than a 30 minute shift in circadian rhythm.

In the method, the strain that is to be mutagenized is treated with a mutagenic agent that induces mutations in the germline. It is important, for reasons associated with subsequent detection and isolation of mutants of interest, that the mutagen be an efficient point mutagen that can induce at least one mutation per locus per 500 gametes in the founder animal strain. Ethylnitrosourea (ENU) is a suitable and preferred mutagen which introduces almost exclusively point mutations in the mouse germline. A suitable protocol for ENU mutagenesis of mice is described in Shedlovsky et al., *Genet. Res., Camb.* 47:135-142 (1986), incorporated herein by reference. It is preferred, but not essential, that the mutagenesis be performed on male mice, since it is possible to obtain many offspring from a single mutagenized male. The mice are then crossed with unmutagenized mice of the same strain to produce isogenic animals, heterozygous only for the various mutations induced by the mutagenesis.

Each member of the set of Gen1 animals is crossed to mice heterozygous for the mutation conferring the index phenotype. It is desirable to produce up to 1000 of such Gen1 animals, to maximize the statistical likelihood that each of the approximately 1×10^5 genes in the mouse genome is examined at least once. If the mutation frequency is 1 per locus per 500 gametes, a 1000-member library of Gen1 animals would contain an

average of 2 hits for each locus that can modify the index phenotype. The probability that a salient locus would escape attention would then be e^{-2} or $\approx 10\%$. The cross can be done using Gen1 animals of either gender, unless the index phenotype 5 compromises the successful breeding of one gender. It is sometimes possible to foster offspring when the female parent is compromised.

The kindreds are evaluated as follows. The phenotypic behaviors of the full set of Gen1F₁ animals are scored as are the phenotypes of individual kindreds. Where no modification 10 is present, the behavior of individuals in the kindred would range over the average behavior of the full set. However, if a modifying mutation has been induced, and since the founder parent was heterozygous for the modifying mutation, on average 50% of the members of the kindred will show an outlying 15 phenotype.

To improve the statistical likelihood that a modified phenotype is genuine, it is preferred that the modification be observed in two or more animals of a kindred having four or 20 more members. A further condensation of the method is possible under these conditions. See, *infra*. It is most preferred that the kindred have at least six members and that three or more members are affected. It may be fruitful, however, to study smaller kindreds containing a single extreme outlier.

The female parents of kindreds that evidence possible 25 modification by the above-noted standard are then crossed to unmutagenized mice of the same founder strain to maintain the mutation on a fixed background (a "copying generation"). The offspring of the copying generation are crossed again to mice 30 heterozygous for the chosen phenotype to assess whether any of their offspring carry a *bona fide* modifying mutation. A genotypic analysis can be performed to determine which of these 35 offspring carry the gene that confers the index phenotype. It can be particularly important to characterize the offspring quickly if the phenotype is one that affects the lifespan of the Gen1 founder animals.

Mice shown by genotypic analysis to carry the index

determinant are assessed as early as possible to determine whether any modification is apparent. If such a modified phenotype is observed, the specific genetic sequences responsible for the modification can be systematically identified using technology now available to the art. See, e.g., Zhang, Y. et al, "Positional cloning of the mouse *obese* gene and its human homologue," Nature 372:425-432 (1994); Kusumi, K. et al., "The mouse pudgy mutation disrupts Delta homologue D113 and initiation of early somite boundaries," Nature Genetics, 19:274 (1998); and King, D. P., et al., "Positional Cloning in the Mouse Circadian Clock Gene," Cell 89:641 (1997), all incorporated herein by reference in their entirety. Each gives a concrete example of mutation-guided positional cloning. In the latter example, mutations were induced with ENU. In this approach, murine coding sequences are identified on a contig (a contiguous nucleic sequence of a portion of a chromosome determined by analyzing of a set of overlapping component nucleic acid sequences) constructed in the region of markers linked to a mutation. The murine coding sequences were identified by exon trapping (Church, D. M., et al, Nature Genet. 6:98-105 (1994), incorporated herein by reference), sequencing of trapped exons, comparing the sequences of trapped exons to all sequences in Genbank, screening putative exons for the presence of corresponding RNA in a variety of tissues by northern blots and reverse-transcription PCR. Then, by known methods of hybridization to human genetic material, the corresponding human gene was obtained. Alternatively, PCR primers prepared from the murine genetic sequences can be used to amplify corresponding human sequences from human genetic material. One skilled in the art can readily determine the similarity required between murine-derived primers and human target sequences in PCR methods.

While the method described above is effective for finding segregating mutations that modify an index phenotype, the method is improved by providing a first improved method that more rapidly identifies modifiers having a severe and

pronounced heterozygous enhancing or suppressing impact on an index phenotype, or by providing a second improved method that facilitates identifying and mapping modifiers by reducing genetic background noise. The improved methods are described below.

It is also noted that male gametes can now be advantageously harvested at sexual maturity (approximately 6 weeks for mice) and preserved indefinitely or used in an *in vitro* fertilization method, for example, according to the published method of Sztein, J.M., J.S. Farley J.S., A.F. Young and L.E. Mobraaten, "Motility of cryopreserved mouse spermatozoa affected by temperature of collection and rate of thawing," *Cryobiology* 35 (1):46-52 (1998), incorporated herein by reference in its entirety. By using the cryopreservation method, germplasm found to comprise a modifying mutation can be rescued and used in any cross described herein, even if the source animal is, at the time, too old or too ill to breed. Each male yields sufficient sperm to produce at least 500 progeny. In each cross described, it is also preferred that animals (or, more broadly, gametes) that potentially contribute a modifier into the cross be male animals (or gametes), unless a maternal effect is involved in the index phenotype, because so many more gametes can be screened using males rather than females. Depending upon the strains used, foster mothering may be required.

The first improved method, which is more compact and more efficient than the prior method, requires fewer crossing steps, eliminates a holding generation, and can be useful where the modified index phenotype accelerates death or reduces breeding capacity. This improved method sacrifices some of the strength of the 2-generation dominant modifier screen in that it does not present a candidate on the basis of a cluster of outliers on the survival curve and in that it loses strict isogenicity after the first generation. However, it does aim efficiently at modifiers in vital genes whose cloning can be pursued as described. In this improved method, one can detect new modifier alleles, both for extreme enhancer and suppressor

outliers in the F_1 generation, or instead can use the cluster principle of the basic method to confirm subtle F_1 outliers by screening for clusters of animals more subtly modified in the backcross (N2) generation. An "extreme" outlying phenotype can be defined on a case-by-case basis, depending upon the nature of the index phenotype. A non-limiting example would be a phenotype enhanced or suppressed to a level below the tenth percentile or above the ninetieth percentile, respectively. In another case, for example, "extreme" levels might be established at the second and ninety-eighth percentiles. A "subtle" change is a change that is within statistical noise in the F_1 animals, but first becomes statistically significant in the backcross generation or subsequent cross.

In the first improved method, a mutagenized inbred animal of an appropriate strain is mated directly to an animal of the index strain to produce F_1 progeny that are screen for modified index phenotype.

If an F_1 animal appears to carry a modifier mutation, it is backcrossed to the index strain (with or without the index allele) to yield N2 progeny. At this generation, multiple animals are screened to find clusters of progeny with a modified phenotype. Clusters of animals that exhibit the modified phenotype carry the modifier mutation, while those that do not exhibit the modification fail to carry the mutation. Carriers must be heterozygous for alleles genetically linked to the locus, while non-carriers must be homozygous for the index strain at those same loci. Thus, these animals provide the material for mapping the new mutation using well-known PCR-based mapping methods (SSLPs and SNPs). Single nucleotide polymorphisms are described in Kruglyak, L. "The Use of a Genetic Map of Biallelic Markers in Linkage Studies," *Nature Genetics* 17:21 (1997), incorporated herein by reference in its entirety.

The second improved method facilitates identifying and mapping of modifying mutations by reducing genetic background noise. The method is an isogenic modifier screening method in which animals that contribute the dominant allele and the

founder inbred animals that carry random point mutations share an inbred genetic background. Apart from the dominant index allele, the index animals are closely matched to the mutation-carrying founder inbred animals.

5 Two embodiments of this second improved method are contemplated. In the first embodiment, enhancer and suppressor modifiers can both be detected when the genetic background shared by the index animals and the founder animals has no apparent effect on the index phenotype. In an example of this 10 embodiment, an index mouse strain can contain a *Min* allele at an *Apc* locus on a C57BL/6J (B6) background while the mutagenized founder animals can be B6 mice.

15 In the second embodiment of this method, the genetic background affects the index phenotype, in that when the dominant allele that confers the index phenotype is provided on a particular genetic background, the index phenotype is enhanced or suppressed in the animal, facilitating selective detection of suppressing or enhancing modifiers, respectively. The index strain can be a congenic derivative of a strain that has a genetic background that enhances or suppresses the index 20 phenotype, wherein the congenic strain carries the dominant allele that confers an index phenotype. For example, in a congenic strain having a *Min* allele at an *Apc* locus, on the genetic background of the inbred BTBR strain, the *Min* phenotype 25 is significantly enhanced.

Congenic inbred animals carrying the index allele are crossed to animals that have been mutagenized as described elsewhere herein to produce Gen1 animals. Suppression and/or enhancement of the index phenotype can be assessed as 30 described. Where the index parent in this cross has an enhanced index phenotype, putative suppressing modifiers of the index phenotype can be apparent in some Gen1 animals as a shift in the index phenotype away from the enhanced level and toward the wild-type level. Putative modifiers in Gen1 animals can be 35 mapped by crossing the Gen1 animals to a genetically distinguishable inbred strain.

In each instance, to facilitate mapping and cloning of a

putative modifier, animals that contain a putative modifier are crossed to genetically distinguishable germplasm because mapping methods demand differences between the animals that contain putative modifiers and strains used for mapping.

5 However, polymorphic differences in the genetic backgrounds of these strains can obscure the phenotype modification exerted by an induced enhancer or suppressor mutation. This problem can be overcome by creating an index strain that differs from the founder strain only at single nucleotide polymorphisms (SNPs)

10 peppered about its genome. Briefly, an isogenic index strain is created by mutagenizing the index strain using a mutagen that induces single nucleotide changes, such as ENU. The SNP-marked index strain is created by systematic brother-sister mating, starting with a son and a daughter of the mutagenized

15 animal who had been mated to the animal carrying the index mutation. The process of sequential brother-sister sib-mating gradually eliminates detrimental and lethal mutations. To validate that the introduced SNP markers are phenotypically neutral, the index phenotype of the SNP-marked strain can be assessed. By way of example, ENU mutagenesis of BTBR or B6

20 mouse strains can be expected to produce such marker polymorphisms at a density in the range of 1 per centiMorgan. The approach of preparing such an index strain permits genetic screens to be as close to isogenic as one can envision.

25 The methods for identifying heterozygous carriers of enhancers and suppressors of an index phenotype can be effectively guided by applying an appropriate statistical analysis to the phenotypic data in candidate kindreds (e.g., tumor count, in the case of *Min*). Using the algorithm, it is possible to enhance the efficiency with which one identifies 30 likely carriers and noncarriers of a candidate heterozygous modifier gene.

35 The first part of a suitable two-part statistical analysis, confirms the presence of a modifier gene segregating in a candidate kindred by applying a likelihood ratio test of the null hypothesis that no phenotype-modifying gene is segregating. The likelihood ratio test considers the

alternative hypothesis that one modifier gene is segregating, and the test is calibrated exactly by Monte Carlo; that is, a p-value is obtained by calculating the likelihood ratio statistic repeatedly for random permutations of animals among 5 subkindreds. For a discrete phenotype such as tumor count, background and modified phenotype distributions are modeled as negative binomials. Gaussian distributions may be appropriate for continuous phenotypes. If the p-value > 0.05, there is no evidence for a modifier gene. Either more data are needed, or 10 different kindreds should be considered for further analysis.

If the p-value < 0.05, then, in the second part of the analysis, a LOD score for the presence of the modifier gene is calculated for each potential carrier that has offspring with phenotype information. The LOD score is the base 10 logarithm 15 of the ratio of the probability of offspring phenotype data if the animal carries the modifier gene compared to the probability of the phenotype data if the animal does not carry the modifier gene. Probabilities are calculated from an estimated background distribution for the denominator, and from a mixture of the estimated background and estimated modified 20 distribution for the numerator. Estimated distributions are obtained by the method of maximum likelihood. Negative binomial distributions can be used for tumor count phenotype, and Gaussian distributions can be used for continuous phenotypes. Potential carriers are then ranked according to 25 their LOD scores. Mapping proceeds by first analyzing animals with highest positive LOD scores (likely carriers) and highest negative LOD scores (likely noncarriers).

An ENU-induced modifier mutation can be mapped to low 30 resolution on the basis of their heterozygous phenotype, as outlined above. As detailed near the end of the Example below, higher resolution mapping is available when homozygotes for the ENU-induced modifier mutation have a qualitatively distinct phenotype such as lethality.

35 The invention will be better understood upon consideration of the following non-limiting Example.

Example

The *Min* mutation, described by Moser et al., "A Dominant Mutation that Predisposes to Multiple Intestinal Neoplasia in the Mouse," *Science* 247:322-324 (1990), incorporated herein by reference, is a dominantly transmitted, fully penetrant mouse mutation that causes a phenotype in heterozygotes that closely resembles human inherited colonic polyposis syndromes. In this example, C57BL/6 mice carrying the *Min* allele were bred with genetically-distinguishable BTBR mice that carried random point mutations inherited from mutagenized fathers.

At approximately 1 month intervals, 6 to 12 male BTBR mice were treated with ENU according to the protocol described by Shedlovsky, *supra*, and were then crossed to female, unmutagenized BTBR mice. The Gen1 offspring of that cross were isogenic BTBR animals heterozygous for possible mutations that could affect the tumor load in mice that contain the *Min* mutation. Approximately 900 female Gen1 offspring were obtained over time.

Two hundred ninety-five Gen1 female mice were crossed with B6-*Min* male mice. As an aside, it is noted that multiple Gen1 males could have been crossed with B6-*Min* females, if the litters had been raised by foster mothers (such as ICR mice, commercially available) within a few days of birth. Over 90% of such pups survive. This strategy would be advantageous in that by providing multiple B6-*Min* females, production of a sufficient number of Gen1F₁ animals would be accelerated.

To perform the cross, two females and one male were placed in a cage. After two weeks, the females were withdrawn and replaced by two new females. Pregnancies were detected by weekly palpation of separated females. If no pregnancy was detected after two weeks of separation, the female was recycled into matings. The Gen1F₁ progeny from each female were genotyped for *Min* and were screened for signs of illness twice weekly starting at 100 days of age. When the animals began to look pale they were screened daily until they appeared close to death. The genotypic analysis employed allele-specific PCR or allele-specific hybridization, as described by Dietrich et al.,

supra, at page 637, and papers cited therein, all incorporated herein by reference, using the same PCR primers and conditions used by Dietrich et al.

Among the progeny were 92 kindreds having 6 or more members. Of these 92 kindreds, 5 kindreds showed at least two *Min*/+ members with possible enhancement of the *Min* phenotype (that is, a survival time shorter than the 90th percentile survival of the total population of Gen1F₁ mice). Seven kindreds showed at least two *Min*/+ members with suppression of the *Min* phenotype (that is, longer survival than the 10th percentile). As expected, the enhancement or suppression of the phenotype segregated within a kindred, since the *Min* mice in the Gen1F₁ generation of a kindred are heterozygous for any newly-induced mutations.

15 The following table shows survival of four kindreds that include segregating candidate enhancer or suppressor loci:

Kindred Number	Mouse Number	Born	Died	Last Age	% survival on Gen1F ₁ curve
20	Su248	1	10/20/yr1	11/11/yr2	388
		3	10/20/yr1	08/21/yr2	306
		2	10/20/yr1	07/26/yr2	280
		6	10/20/yr1	04/12/yr2	175
25	Su258	4	10/11/yr1	11/12/yr2	398
		2	10/11/yr1	10/16/yr2	371
		14	02/14/yr2	09/30/yr2	229
		6	12/13/yr1	07/01/yr2	201
30		7	12/13/yr1	06/19/yr2	189
		3	10/11/yr1	04/16/yr2	188
		11	12/13/yr1	05/25/yr2	164
35	En333	15	03/06/yr2	08/05/yr2	152
		3	10/25/yr1	03/14/yr2	141
		12	03/06/yr2	07/23/yr2	139
		2	10/25/yr1	03/12/yr2	139
40		13	03/06/yr2	06/18/yr2	104
		11	03/06/yr2	06/18/yr2	104
		10	03/06/yr2	06/18/yr2	104
		17	03/06/yr2	06/18/yr2	104
45	En425	3	11/10/yr1	04/05/yr2	147
		1	11/10/yr1	03/25/yr2	136
		2	11/10/yr1	03/12/yr2	123
		6	11/10/yr1	03/12/yr2	123
		8	11/10/yr1	02/27/yr2	109
		6	11/10/yr1	02/27/yr2	109

If the probability is 10% that a mouse of normal genotype will survive longer than a particular age, the random probability that 2 mice in the same kindred will survive longer than that age is only 1%. The random probability that 3 mice in a kindred will survive longer is only 0.1%, in turn. 5 Therefore, as the number of members of a kindred having an outlying short or long survival increases, so does the likelihood that the deviation results from a *bona fide* mutation inherited from the mutagenized BTBR founder animal. This is 10 the cluster principle of the method. By predetermining a desired level of clustering, one can set limits on the ability to detect mutants and can raise the purification level of mutants obtained, thereby enriching the screen for mutants.

Fig. 1 depicts the probability of survival versus age in the Gen1F₁ generation of the cross between Gen1 BTBR females and B6-Min males. The symbols below and to the left of the curve reflect individuals in 2 kindreds thought to contain mutations that enhance the Min phenotype (En333 and En425). The symbols above and to the right of the curve reflect the members of 2 kindreds for whom the Min phenotype appears to be suppressed (Su248 and Su258). A number of the mice in the latter category remained alive at more than 365 days of age. Mice that showed statistically lower or higher survival were bred using standard methods to maintain the mutation. In some cases, the Gen1 animal failed to breed and the long term surviving Gen1F₁ mice were bred to the wild-type founder strain instead, as a fallback method for rescuing mutations of interest. For example, the founder parent of kindred Su258, described *infra*, was not able breed after a candidate mutation 20 was identified in her progeny. Long-lived progeny animals 25 number 2 and 4 were, therefore, bred to BTBR mice.

To verify that these outlying members of a kindred do indeed contain an enhancing or suppressing mutation, a 30 second-generation kindred was examined. This is useful both to recover carriers of a strong enhancer mutation and to detect more subtle dominant affects of either the suppressor or the enhancer class. Commonly, heterozygotes for a loss of gene

function show only a subtle heterozygous effect.

To produce the second generation kindred, the founder animal that gave rise to a kindred that evidenced either an enhancing or suppressing function was crossed to normal BTBR animals. On average, 50% of the offspring of this cross would be expected to contain the suppressing or enhancing mutation. The offspring of this cross, termed Gen2, were crossed to B6-*Min* mice.

After 90 days, the progeny shown by genotypic analysis to carry the *Min* mutation were sacrificed and tumor load was assessed using standard methods for determining average tumor volume and number. Tumor load is defined as average tumor volume times the number of tumors per mouse.

As further proof that a suppressing mutation was obtained in kindred 258, two of the long-term survivors in the Gen1F₁ generation were bred and descendants were found to have very low tumor counts (about 10 or fewer tumors). This provided strong evidence that a bona fide mutation having the effect of suppressing the *Min* phenotype was segregating upon passage to the offspring. On the basis of 699 animals in suppressor kindred 258, the statistically estimated tumor multiplicity of +/+ animals is 18.8, on average, while that of the Su/+ animals is estimated as 5.9. For enhancer kindred 333, the estimated tumor multiplicity of the +/+ animals is 20.5 while the En/+ members of the kindred have an estimated tumor multiplicity of 36.

Because of the known SSLP polymorphisms between B6 and BTBR DNA, it will be possible to isolate the portion of the progeny genome that contains BTBR DNA and thereafter to localize the point mutation responsible for modifying the phenotype using standard techniques now available to the skilled molecular geneticist. The fact that ENU-induced mutations are single basepair substitutions makes this step particularly powerful. This is the basis for the "Modifying Molecule" appellation of the ICMM method. The portion of the genome containing the point mutation can be compared against known ESTs, or can be sequenced *de novo* to determine the

genetic sequence responsible for encoding the molecule that
5 modifies the phenotype. Using standard methods, the genetic
sequence can be introduced into a suitable genetic construct
containing a transcriptional promoter for production in a
prokaryotic or eukaryotic host cell. One could use the cloned
gene to produce other mutations in this gene in companion mouse
strains.

10 The genetic sequence is readily compared against known
sequences from humans to determine the identity of the
corresponding human gene. The human gene can be isolated by
standard methods of hybridization, PCR, or expression cloning.
The human protein can likewise be obtained using standard
techniques, either by isolation from human tissue, or by
production in a non-native host using recombinant DNA methods.

15 It may be possible to isolate mutations that suppress the
index *Min* phenotype in a more compact, albeit less sensitive,
method. In this method, B6-*Min* (heterozygous) female mice are
crossed directly with ENU-mutagenized BTBR male mice. As a
control, non-mutagenized BTBR male mice are also processed in
20 the same way. The *F*₁ offspring are fostered on ICR mice. Male
*F*₁ mice that have the *Min* phenotype are maintained.

25 At 170 days, any *Apc*^{*Min/+*} *F*₁ male whose body weight is
greater than 95% of the control body weight is considered a
candidate carrier of a dominant suppressor of the *Min*
phenotype, *Su/+*.

Such candidate carriers are bred at 170 days of age to
wild-type B6 female mice. The female offspring of this cross
(*Apc*^{*Min/+*} and *Apc*^{*+/+*}) are backcrossed to the candidate male who is
by now only about 230 days old.

30 The progeny of the latter cross are then phenotyped at 90
days of age. By this time, the candidate male is at least 340
days old. Among the progeny, any detrimental or lethal
phenotypes will inform about the map position of the suppressor
and will indicate whether the candidate male carries a
35 suppressor mutation.

15 *Apc*^{Min/+} Progeny:

+/+ normal *Min* phenotype
Su/+ low tumor load at 90 days?
Su/Su very low tumor load at 90 days?
5 or detrimental or lethal?

10 *Apc*^{+/+} Progeny:

+/+ normal
Su/+ normal?
Su/Su detrimental or lethal?

15 Detrimentally affected animals will be homozygous for BTBR markers linked to the suppressor locus. By contrast, if *Su/Su* is an embryonic lethal mutation, the set of liveborn progeny will lack animals homozygous for BTBR markers linked to the suppressor locus.

20 It may also be important to rescue germplasm carrying a modifier mutation that enhances or suppresses, but particularly those that enhance, the *Min* phenotype, using *in vitro* fertilization. For example, a candidate carrier male who might be too sick to breed can be sacrificed. Sperm taken from the sacrificed male can be used to fertilize eggs obtained from a suitable female (e.g., BTBR or a mouse that carries the mutation of interest). The techniques that can be employed are described in Hogan, B. et al., Manipulation of the Mouse Embryo, Cold Spring Harbor Laboratory Press, 2nd. ed. (1994), incorporated herein by reference.

25 It is intended that the foregoing examples are non-limiting on the invention, but rather that the invention encompasses all such modifications and variations as come within the scope of the following claims.

CLAIMS

WE CLAIM:

5 1. A method for identifying a segregating mutation at a genetic locus that modifies an index phenotype in an index inbred strain, the segregating mutation causing an outlying phenotype relative to the index phenotype, the method comprising the steps of:

10 outcrossing a founder inbred strain to an index inbred strain to obtain F₁ progeny, the founder inbred strain carrying random point mutations relative to a wild-type animal of the founder inbred strain, the index inbred strain carrying a dominant allele at a locus known to confer the index phenotype and being genetically distinguishable from the founder inbred strain, wherein some of the F₁ progeny that carry the dominant allele also carry at least one random mutation;

15 20 backcrossing the F₁ progeny to the index inbred strain, with or without the index allele, to obtain N2 backcross progeny, wherein at least some of the N2 backcross progeny that carry the dominant allele also exhibit the outlying phenotype; and

25 verifying that the outlying phenotype is caused by a segregating mutation.

30 2. A method as claimed in Claim 1 wherein any of the crosses employ preserved gametes.

35 3. A method as claimed in Claim 1 wherein the F₁ progeny and some of the N2 progeny exhibit an extreme outlying phenotype.

4. A method as claimed in Claim 3 wherein the segregating mutation is a heterozygous modifier of the index phenotype selected from a group consisting of an enhancing modifier and a suppressing modifier.

5

5. A method as claimed in Claim 1 wherein the dominant allele is a *Min* allele at an *Apc* locus.

10

6. A method as claimed in Claim 1 wherein the index inbred strain is an isogenic index strain that carries single nucleotide polymorphisms.

15

7. A method as claimed in Claim 6 wherein the isogenic index strain is produced by a method comprising the steps of:
treating an animal of an index strain with a mutagenic agent to induce point mutations in the treated animal;
crossing the treated animal to an animal of the index strain to produce F1 progeny; and
sib-mating F1 and subsequent generation progeny until detrimental and lethal mutations are eliminated.

20

8. A method as claimed in Claim 1 wherein the founder inbred mouse strain is produced by a method comprising the step of treating a wild-type inbred mouse with a mutagenic agent to induce point mutations.

25

9. A method as claimed in Claim 8 wherein the mutagenic agent is ethylnitrosourea.

30

10. A method for identifying a human genetic sequence that corresponds to a segregating mutation at a genetic locus in a non-human animal, the segregating mutation causing an outlying phenotype relative to an index phenotype in an index 5 inbred mouse strain, the method comprising the steps of:

outcrossing a founder inbred non-human strain to an index inbred non-human strain to obtain F₁ progeny, the founder inbred strain carrying random point mutations relative to a wild-type animal of the founder inbred strain, the index inbred 10 strain carrying a dominant allele at a locus known to confer the index phenotype and being genetically distinguishable from the founder inbred strain, wherein some of the F₁ progeny that carry the dominant allele also carry at least one random mutation;

15 backcrossing the F₁ progeny to the index inbred strain, with or without the index allele, to obtain N2 backcross progeny, wherein at least some of the N2 backcross progeny that carry the dominant allele also exhibit the outlying phenotype;

20 verifying that the outlying phenotype is caused by a segregating mutation;

identifying genetic markers linked to the segregating mutation;

identifying a gene on a contig that encodes the segregating mutation; and

25 recovering human genetic sequences that correspond to the mutation-encoding gene.

11. A method for identifying a segregating mutation at a genetic locus that modifies an index phenotype in an index inbred strain, the segregating mutation causing an outlying phenotype relative to the index phenotype, the method comprising the steps of:

5 crossing a founder inbred strain with an index inbred strain to obtain Gen1 progeny, the founder inbred strain carrying random point mutations relative to a wild-type animal of the founder inbred strain, the index inbred strain carrying a dominant allele at a locus known to confer the index phenotype, the allele being provided on a genetic background of the wild-type founder inbred strain, wherein some of the Gen1 progeny that carry the dominant allele also exhibit a modified index phenotype; and

10 15 verifying that Gen1 progeny that carry the dominant allele and exhibit a modified index phenotype carry a segregating mutation.

20 20 12. A method as claimed in Claim 11 wherein the genetic background has no modifying effect upon the index phenotype.

25 25 13. A method as claimed in Claim 11 wherein the genetic background has a modifying effect upon the index phenotype.

30 14. A method as claimed in Claim 13 wherein the genetic background has an enhancing effect upon the index phenotype, and wherein the Gen1 animals exhibit a suppressed phenotype relative to the index inbred strain.

15. A method as claimed in Claim 11 further comprising
the steps of:

mapping the segregating mutation by crossing Gen1 animals
that have the dominant allele and a modified index phenotype to
5 a genetically distinguishable inbred strain; and
evaluating the progeny of the mapping cross.

16. A method as claimed in Claim 15 wherein the
10 genetically distinguishable inbred strain is an inbred strain
having the genetic background of the wild-type founder inbred
strain and further comprising single nucleotide polymorphisms
relative to the wild-type founder inbred strain.

15 17. A genetically altered mouse having a genetic
background characteristic of a first inbred mouse strain, the
mouse comprising in its genome:

20 a dominant heterozygous allele that confers an index
phenotype on a mouse having the characteristic genetic
background; and

25 a segregating modifier of the index phenotype, the
modifier being genetically linked to a genetic marker
characteristic of a second inbred mouse strain,

wherein the index phenotype in the genetically altered
mouse is modified relative to the index phenotype in a mouse
that comprises the dominant allele on the genetic background
characteristic of the first inbred mouse strain but which lacks
the segregating modifier.

30 18. A mouse as claimed in Claim 17 wherein the dominant
allele is a *Min* allele at an *Apc* locus.

35

19. A non-human animal comprising a segregating mutation that modifies an index phenotype, the animal being prepared according to a method comprising the steps of:

5 outcrossing a founder inbred non-human strain to an index inbred non-human strain to obtain F₁ progeny, the founder inbred strain carrying random point mutations relative to a wild-type animal of the founder inbred strain, the index inbred strain carrying a dominant allele at a locus known to confer the index phenotype and being genetically distinguishable from the founder inbred strain, wherein some of the F₁ progeny that carry the dominant allele also carry at least one random mutation;

10 backcrossing the F₁ progeny to the index inbred strain, with or without the index allele, to obtain N2 backcross progeny, wherein at least some of the N2 backcross progeny that carry the dominant allele also exhibit the outlying phenotype;

15 verifying that the outlying phenotype is caused by a segregating mutation; and

20 selecting an animal that shows the outlying phenotype.

20. A non-human animal as claimed in Claim 19 wherein the non-human animal is a mouse.

5 21. A non-human animal comprising a segregating mutation that modifies an index phenotype, the animal being prepared according to a method comprising the steps of:

10 crossing a founder inbred strain with an index inbred strain to obtain Gen1 progeny, the founder inbred strain carrying random point mutations relative to a wild-type animal of the founder inbred strain, the index inbred strain carrying a dominant allele at a locus known to confer the index phenotype, the allele being provided on a genetic background of the wild-type founder inbred strain, wherein some of the Gen1 progeny that carry the dominant allele also exhibit a modified index phenotype;

15 verifying that Gen1 progeny that carry the dominant allele and exhibit a modified index phenotype carry a segregating mutation; and

20 selecting an animal that shows the outlying phenotype.

25 22. A non-human animal as claimed in Claim 21 wherein the non-human animal is a mouse.

23. A non-human animal comprising a segregating mutation that modifies an index phenotype, the animal being prepared according to a method comprising the steps of:

5 outcrossing a founder isogenic inbred strain with the index inbred strain to obtain Gen1F₁ progeny, the founder isogenic strain being heterozygous only for random point mutations relative to a wild-type animal of the founder inbred strain, the index inbred strain carrying a dominant allele at a locus known to confer the index phenotype, where at least some 10 of the Gen1F₁ progeny carry both the dominant allele and at least one random mutation;

15 crossing a founder animal of the founder isogenic inbred strain to an animal of the founder strain that lacks the mutations to obtain inbred Gen2 offspring, where the founder animal has at least one outcrossed F₁ progeny that displays the outlying phenotype relative to the index phenotype;

20 outcrossing Gen2 offspring to the index strain to obtain Gen2F₁ backcross progeny, half of which, on average, carry the dominant allele that confers the index phenotype; and

25 verifying that a subset of the Gen2F₁ progeny shows the outlying phenotype; and

 selecting an animal that shows the outlying phenotype.

24. A non-human animal as claimed in Claim 23 wherein the non-human animal is a mouse.

25. A method for identifying a segregating mutation at a genetic locus that modifies an index phenotype in an index inbred strain, the segregating mutation causing an outlying phenotype relative to the index phenotype, the method comprising the steps of:

outcrossing a founder isogenic inbred strain with the index inbred strain to obtain Gen1F₁ progeny, the founder isogenic strain being heterozygous only for random point mutations relative to a wild-type animal of the founder inbred strain, the index inbred strain carrying a dominant allele at a locus known to confer the index phenotype, where at least some of the Gen1F₁ progeny carry both the dominant allele and at least one random mutation;

crossing a founder animal of the founder isogenic inbred strain to an animal of the founder strain that lacks the mutations to obtain inbred Gen2 offspring, where the founder animal has at least one outcrossed F₁ progeny that displays the outlying phenotype relative to the index phenotype;

outcrossing Gen2 offspring to the index strain to obtain Gen2F₁ backcross progeny, half of which, on average, carry the dominant allele that confers the index phenotype; and

verifying that a subset of the Gen2F₁ progeny shows the outlying phenotype.

ABSTRACT OF THE DISCLOSURE

Methods for breeding mutagenized mice permit detection of genetic loci that in heterozygous mutated form can modify a known index phenotype involves crossing a mutagenized founder strain and a second strain of mice carrying an allele at a locus that confers the index phenotype. In the test generation, clusters of individuals are observed to deviate from the typical phenotype. The genetic material and molecules encoded thereby can be obtained using available methods.

Improved and compact methods are also disclosed.

SEQUENCE LISTING

Not applicable.

5

10 QBMAD\164075

The ICMM Method




FIG 1

Please type a plus sign (+) inside this box 96010/PTO
Rev. 6/95U.S. Department of Commerce
Patent and Trademark Office

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION

Declaration OR Declaration
 Submitted Submitted after
 with Initial Filing Initial Filing

Attorney Docket Number	960296.95491
First Named Inventor	William F. Dove
<i>COMPLETE IF KNOWN</i>	
Application Number	
Filing Date	
Group Art Unit	
Examiner Name	

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHOD FOR IDENTIFYING MUTANTS AND MOLECULES

(Title of the Invention)

the specification of which

is attached hereto

OR

was filed on (MM/DD/YY) as United States Application Number or PCT International

Application Number and was amended on (MM/DD/YY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YY)	Priority Not Claimed	Certified Copy Attached? YES	Certified Copy Attached? NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Additional foreign applications numbers are listed on a supplemental priority sheet attached hereto:

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.
<input type="text"/>	<input type="text"/>	<input type="checkbox"/>

Burden Hour Statement: This form is estimated to take .4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
OMBAD:165588

Please type a plus sign (+) inside this box

DECLARATION

Page 2

I hereby claim benefit under Title 35, United States Code §120 of any United States application(s), or §1365(c) of any PCT international application, comprising the United States of America, filed, or priority claimed in the subject application, or any continuation, divisional, or corresponding application, filed in the United States or application(s) or PCT international application(s) in the manner provided in the first paragraph of Title 35, United States Code §112; I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YY)	Parent Patent Number (if applicable)
08/751,292		11/18/96	

Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and all continuation and divisional applications based thereon, and to transact all business in the Patent and Trademark Office connected therewith:

<input type="checkbox"/> Firm Name	<input type="checkbox"/> Customer Number or label
OR	
<input checked="" type="checkbox"/> List attorney(s) and/or agent(s) name and registration number below	

Name	Registration Number	Name	Registration Number
Thad F. Kryshak	19,428	Gregory A. Nelson	30,577
Neil Hamilton	19,669	Keith M. Baxter	31,233
Thomas W. Ehrmann	20,374	John D. Franzini	31,166
Barry E. Sammons	25,608	Joseph W. Bain	34,230
J. Rodman Steele	25,711	Robert A. Sacco	35,667
Nicholas J. Seay	27,386	Jean C. Baker	35,433
George E. Haase	27,642	David G. Ryser	35,407
Michael J. McGovern	28,326	Bennett J. Berson	37,094
Carl R. Schwartz	29,437	Michael A. Jaskolski	37,551

Additional attorney(s) and/or agent(s) named on a supplemental priority sheet attached hereto.

Please direct all correspondence to Customer Number or label Fill in correspondence address below

Name: Bennett J. Berson
Address: Quarles & Brady
Address: P O Box 2113
City: Madison State: WI Zip: 53701-2113
Country: US Telephone: 608/251-5000 Fax: 608/251-9166

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Name of Sole or First Inventor: A petition has been filed for this unsigned inventor
Given Name: William Middle Name: F. Family Name: Dove Suffix: Jr.
Inventor's Signature:  Date: 7.14.98

Residence: City: Madison State: WI Country: US Citizenship: US

Post Office Address: 4130 Mandan Crescent

Post Office Address:

City: Madison State: WI Zip: 53711 Country: US Applicant Authority:

Additional inventors are being named on supplemental sheet(s) attached hereto

Please type a plus sign (+) inside this box

DECLARATION				ADDITIONAL INVENTOR(S) Supplemental Sheet				
Name of Additional Joint Inventor, if any:				A petition has been filed for this unsigned inventor				
Given Name	Alexandra	Middle Initial	Family Name	Shedlovsky		Suffix e.g. Jr.		
Inventor's Signature	<i>Alexandra Shedlovsky</i>					Date	July 14, 1998	
Residence: City	Madison	State	WI	Country	US	Citizenship	US	
Post Office Address	4130 Mandan Crescent							
Post Office Address								
City	Madison	State	WI	Zip	53711	Country	US	Applicant Authority
Name of Additional Joint Inventor, if any:				A petition has been filed for this unsigned inventor				
Given Name				Middle Initial	Family Name			Suffix e.g. Jr.
Inventor's Signature						Date		
Residence: City				State		Country		
Post Office Address								
Post Office Address								
City				State	Zip			Applicant Authority
Name of Additional Joint Inventor, if any:				A petition has been filed for this unsigned inventor				
Given Name				Middle Initial	Family Name			Suffix e.g. Jr.
Inventor's Signature						Date		
Residence: City				State		Country		
Post Office Address								
Post Office Address								
City				State	Zip			Applicant Authority
Additional inventors are being named on supplemental sheet(s) attached hereto								